Chromium therapy for insulin resistance associated with HIV-disease

Journal of AIDS and Clinical Research

Volumn 4, Issue 9, 2013, Pages

  Stein, Seth A ^a   McNurlan, Margaret ^a   Phillips, Brett T ^a   Messina, Catherine ^a   Mynarcik, Dennis ^a   Gelato, Marie ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chromium picolinate; Glucose intolerance; Prediabetes

Indexed keywords

EID: 84886008074     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000239     Document Type: Article

References (55)

1. Grinspoon S, Carr A (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352: 48-62.
2. Guaraldi G, Stentarelli C, Zona S, Orlando G, Carli F, et al. (2010) Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 208: 222-227.
3. Ford ES (2005) Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 28: 2745-2749.
4. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, et al. (1999) Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63-F70.
5. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, et al. (2005) Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165: 1179-1184.
6. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, et al. (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334: 952-957.
7. Haffner SM (1999) Epidemiological studies on the effects of hyperglycemia and improvement of glycemic control on macrovascular events in type 2 diabetes. Diabetes Care 22 Suppl 3: C54-56.
8. Haffner SM, Miettinen H (1997) Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 103: 152-162.
9. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, et al. (2003) An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 25: 2405-2418.
10. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003.
11. Triant VA, Lee H, Hadigan C, Grinspoon SK (2007) Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92: 2506-2512.
12. Butt AA, Evans R, Skanderson M, Shakil AO (2006) Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. J Hepatol 44: 864-868.
13. Zenilman JM, Hook EW 3rd, Shepherd M, Smith P, Rompalo AM, et al. (1994) Alcohol and other substance use in STD clinic patients: Relationships with STDs and prevalent HIV infection. Sex Transm Dis 21: 220-225.
14. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471.
15. Senior PA (2012) Type 2 diabetes, metformin and lactic acidosis-defining the risk and promoting safe practice. Diabet Med 29: 161-163.
16. Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K (2009) The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database. Clin Ther 31: 2665-2677.
17. Schwarz K, Mertz W (1957) A glucose tolerance factor and its differentiation from factor 3. Arch Biochem Biophys 72: 515-518.
18. Anderson RA, Cheng N, Bryden NA, Polansky MM, Cheng N, et al. (1997) Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46: 1786-1791.
19. Anderson RA, Polansky MM, Bryden NA, Canary JJ (1991) Supplemental-chromium effects on glucose, insulin, glucagon, and urinary chromium losses in subjects consuming controlled low-chromium diets. Am J Clin Nutr 54: 909-916.
20. Anderson RA, Polansky MM, Bryden NA, Roginski EE, Mertz W, et al. (1983) Chromium supplementation of human subjects: Effects on glucose, insulin, and lipid variables. Metabolism 32: 894-899.
21. Cefalu WT, Rood J, Pinsonat P, Qin J, Sereda O, et al. (2010) Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism 59: 755-762.
22. Gürson CT, Saner G (1971) Effect of chromium on glucose utilization in marasmic protein-calorie malnutrition. Am J Clin Nutr 24: 1313-1319.
23. Hopkins LLJr, Ransome-Kuti O, Majaj AS (1968) Improvement of impaired carbohydrate metabolism by chromium 3 in manourished infants. Am J Clin Nutr 21: 203-211.
24. Levine RA, Streeten DH, Doisy RJ (1968) Effects of oral chromium supplementation on the glucose tolerance of elderly human subjects. Metabolism 17: 114-125.
25. Morris BW, Kouta S, Robinson R, MacNeil S, Heller S (2000) Chromium supplementation improves insulin resistance in patients with Type 2 diabetes mellitus. Diabet Med 17: 684-685.
26. Offenbacher EG, Pi-Sunyer FX (1980) Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 29: 919-925.
27. Potter JF, Levin P, Anderson RA, Freiberg JM, Andres R, et al. (1985) Glucose metabolism in glucose-intolerant older people during chromium supplementation. Metabolism 34: 199-204.
28. Urberg M, Zemel MB (1987) Evidence for synergism between chromium and nicotinic acid in the control of glucose tolerance in elderly humans. Metabolism 36: 896-899.
29. Wilson BE, Gondy A (1995) Effects of chromium supplementation on fasting insulin levels and lipid parameters in healthy, non-obese young subjects. Diabetes Res Clin Pract 28: 179-184.
30. Neilsen F (1996) Controversial chromium: Does the superstar mineral of the mountebanks 500 receive appropriate attention from clinicians and nutritionists? Nutrition Today 31: 226-233
31. Cerulli J, Grabe DW, Gauthier I, Malone M, McGoldrick MD (1998) Chromium picolinate toxicity. Ann Pharmacother 32: 428-431.
32. Wasser WG, Feldman NS, D'Agati VD (1997) Chronic renal failure after ingestion of over-the-counter chromium picolinate. Ann Intern Med 126: 410.
33. Feiner JJ, McNurlan MA, Ferris RE, Mynarcik DC, Gelato MC (2008) Chromium picolinate for insulin resistance in subjects with HIV disease: a pilot study. Diabetes Obes Metab 10: 151-158.
34. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
35. Gavi S, Feiner JJ, Melendez MM, Mynarcik DC, Gelato MC, et al. (2007) Limb fat to trunk fat ratio in elderly persons is a strong determinant of insulin resistance and adiponectin levels. J Gerontol A Biol Sci Med Sci 62: 997-1001.
36. Gavi S, Qurashi S, Stuart LM, Lau R, Melendez MM, et al. (2008) Influence of age on the association of retinol-binding protein 4 with metabolic syndrome. Obesity (Silver Spring) 16: 893-895.
37. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, et al. (2002) Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: A pilot study. J Acquir Immune Defic Syndr 31: 163-170.
38. Lydic ML, McNurlan M, Bembo S, Mitchell L, Komaroff E, et al. (2006) Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil Steril 86: 243-246.
39. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC (2000) Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 25: 312-321.
40. Shigenaga MK, Ames BN (1991) Assays for 8-hydroxy-2'-deoxyguanosine: a biomarker of in vivo oxidative DNA damage. Free Radic Biol Med 10: 211-216.
41. Ollinger K, Brunmark A (1994) Effect of different oxygen pressures and N,N'-diphenyl-p-phenylenediamine on Adriamycin toxicity to cultured neonatal rat heart myocytes. Biochem Pharmacol 48: 1707-1715.
42. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-924.
43. Cefalu WT, Wang ZQ, Zhang XH, Baldor LC, Russell JC (2002) Oral chromium picolinate improves carbohydrate and lipid metabolism and enhances skeletal muscle Glut-4 translocation in obese, hyperinsulinemic (JCR-LA corpulent) rats. J Nutr 132: 1107-1114.
44. Davis CM, Vincent JB (1997) Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 36: 4382-4385.
45. Wang ZQ, Zhang XH, Russell JC, Hulver M, Cefalu WT (2006) Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr 136: 415-420.
46. Tamae K, Kawai K, Yamasaki S, Kawanami K, Ikeda M, et al. (2009) Effect of age, smoking and other lifestyle factors on urinary 7-methylguanine and 8-hydroxydeoxyguanosine. Cancer Sci 100: 715-721.
47. Balk EM, Tatsioni A, Lichtenstein AH, Lau J, Pittas AG (2007) Effect of chromium supplementation on glucose metabolism and lipids: A systematic review of randomized controlled trials. Diabetes Care 30: 2154-2163.
48. Gunton JE (2005) Chromium supplementation does not improve glucose tolerance, 544 insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of 545 supplementation in subjects with impaired glucose tolerance. Diabetes Care 28: 712-713 547.
49. Iqbal N, Cardillo S, Volger S, Bloedon LT, Anderson RA, et al. (2009) Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr Relat Disord 7: 143-150.
50. Kleefstra N, Houweling ST, Jansman FG, Groenier KH, Gans RO, et al. (2006) Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care 29: 521-525.
51. Anderson RA (1998) Chromium, glucose intolerance and diabetes. J Am Coll Nutr 17: 548-555.
52. Wang ZQ, Qin J, Martin J, Zhang XH, Sereda O, et al. (2007) Phenotype of subjects with type 2 diabetes mellitus may determine clinical response to chromium supplementation. Metabolism 56: 1652-1655.
53. Albarracin CA, Fuqua BC, Evans JL, Goldfine ID (2008) Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 24: 41-51.
54. Aghdassi E, Arendt BM, Salit IE, Mohammed SS, Jalali P, et al. (2010) In patients with HIV-infection, chromium supplementation improves insulin resistance and other metabolic abnormalities: A randomized, double-blind, placebo controlled trial. Curr HIV Res 8: 113-120.
55. Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, et al. (2001) Repeatability characteristics of simple indices of insulin resistance: Implications for research applications. J Clin Endocrinol Metab 86: 5457-5464.